Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health Inc (NY: HIMS )

22.61 +0.82 (+3.76%)
Streaming Delayed Price Updated: 1:02 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health Inc

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
What Is Going On With Hims & Hers Stock?
Big GLP-1 news could have an impact. 
Via The Motley Fool
Top 3 Stocks with Explosive Call Option Activity: What to Watch
Three stocks reported a surge in call option buying recently, showing investors that there could be a path to more upside potential, analysts agree 
Via MarketBeat
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking concerns over patient access to the compounded diabetes and obesity treatment. 
Via Benzinga
Exposures Product Safety
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
There is now a new reason to look into Hims & Hers stock for additional upside, including the new addition to the S&P 600 index alongside double-digit growth. 
Via MarketBeat
Topics Stocks
Exposures US Equities
How Is The Market Feeling About Hims & Hers Health?
Via Benzinga
Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (8 Ratings)
Via Benzinga
Is Hims & Hers Health Stock a Buy?
The risk-reward proposition is pretty one-sided here. 
Via The Motley Fool
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
Growth for its GLP-1 weight loss drugs continues to be robust. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
Via Benzinga
Hims & Hers Health Stock Is Rising Monday: What's Going On?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this week. 
Via Benzinga
Topics Stocks
Exposures US Equities
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over... 
Via Benzinga
Exposures Product Safety
Massive News for Hims & Hers Stock: The Truth About Today's Move
Hims & Hers may not be hurt by GLP-1 news the way investors think. 
Via The Motley Fool
2 Winning Growth Stocks That Are Screaming Buys Right Now
These top stocks are on a winning streak and have the businesses to keep it going. 
Via The Motley Fool
AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday
Via Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli Lilly And Co's (NYSE:LLY) weight-loss and diabetes drugs from its shortage... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks. 
Via The Motley Fool
Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel
Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military personnel, veterans, teachers, nurses, and first responders. The telehealth... 
Via Benzinga
Hims & Hers to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First Responders
From Hims & Hers
Via Business Wire
Hims & Hers Acquisition: How Innovation Will Flourish
Buying a new pharmacy will allow Hims & Hers to expand into new markets. 
Via The Motley Fool
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Telemedicine once seemed like it was going to revolutionize healthcare. 
Via The Motley Fool
Hims & Hers Stock Pops After Massive Acquisition
The healthcare company will be making more of the product it sells. 
Via The Motley Fool
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
Shares of Hims & Hers are falling even as the company has been posting some solid results. 
Via The Motley Fool
Is Hims & Hers Health the Next Teladoc?
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic. 
Via The Motley Fool
Exposures COVID-19
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
Novo Nordisk has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The company-funded study revealed a 7.4% reduction in body-mass index for children... 
Via Benzinga
Exposures Product Safety
Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
Three stocks stand out for investors to consider as they recently had big selloffs. There are fundamental reasons to believe that these discounts won't last 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Four Stocks To Watch This Week - Monday, Sept 9
Inconsistent patchy behavior looks most likely in the very short term, but stocks still have decent potential in the medium term. Stay focused and be patient for the optimal setups near Key Levels. 
Via Talk Markets
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing sustainability challenges. 
Via Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
Lilly just lowered the price of Zepbound. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.